Opening book details…
Can I read Comparative Efficacy and Safety of Infliximab and Vedolizumab Therapy in Patients with Inflammatory Bowel Disease: a Systematic Review and Meta-analysis on EtoBox?
Comparative Efficacy and Safety of Infliximab and Vedolizumab Therapy in Patients with Inflammatory Bowel Disease: a Systematic Review and Meta-analysis by Laurent Peyrin-Biroulet; Perttu Arkkila; Alessandro Armuzzi; Silvio Danese; Jordi Guardiola; Jørgen Jahnsen; Charles Lees; Edouard Louis; Milan Lukáš; Walter Reinisch; Xavier Roblin; Minyoung Jang; Han Geul Byun; Dong-Hyeon Kim; Sung Jeong Lee; Raja Atreya is a Medicine article available to read on EtoBox.
What is Comparative Efficacy and Safety of Infliximab and Vedolizumab Therapy in Patients with Inflammatory Bowel Disease: a Systematic Review and Meta-analysis about?
## Background and aims There are limited comparative data for infliximab and vedolizumab in inflammatory bowel disease patients. ## Methods We conducted a systematic review and meta-analysis to compare the efficacy and safety of infliximab and vedolizumab in adult patients with moderate-to-severe Crohn’s disease or ulcerative colitis. ## Results We identified six eligible Crohn’s disease and seven eligible ulcerative colitis trials that randomised over 1900 participants per disease cohort to infliximab or vedolizumab. In the Crohn’s disease and ulcerative colitis cohorts, infliximab yielded better efficacy than vedolizumab for all analysed outcomes (CDAI-70, CDAI-100 responses, and clinical remission for Crohn’s disease and clinical response and clinical remission for ulcerative colitis) during the induction phase, with non-overlapping 95% confidence intervals. In the maintenance phase, similar proportions of infliximab- or vedolizumab-treated patients achieved clinical response, clinical remission, or mucosal healing in both Crohn’s disease and ulcerative colitis. For the safety outcomes, rates of adverse events, serious adverse events, and discontinuations due to adverse events w
Who reads Comparative Efficacy and Safety of Infliximab and Vedolizumab Therapy in Patients with Inflammatory Bowel Disease: a Systematic Review and Meta-analysis?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Laurent Peyrin-Biroulet; Perttu Arkkila; Alessandro Armuzzi; Silvio Danese; Jordi Guardiola; Jørgen Jahnsen; Charles Lees; Edouard Louis; Milan Lukáš; Walter Reinisch; Xavier Roblin; Minyoung Jang; Han Geul Byun; Dong-Hyeon Kim; Sung Jeong Lee; Raja Atreya
- Publisher
- Springer Science and Business Media LLC
- Published
- 2022
- Language
- EN
- Field
- Medicine (Health Sciences)